CLOs on the Move

New Health Sciences

www.newhealthsciences.com

 
New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

The Bridgeway

The BridgeWay Hospital, located in Central Arkansas, offers an innovative recovery experience at the foothills of the Ouachita Mountains. Here, we offer a continuum of services designed to help children, adolescents, adults and seniors who are experien...

Oncternal

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.

PvP Biologics

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet. The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.

Confluent Medical Technologies

Confluent Medical Technologies is the leading contract manufacturer of Nitinol-based components, balloon components, and balloon catheters.

Pedinol Pharmacal

Pedinol Pharmacal is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.